Interstitial pneumonia after regression by olaparib for neuroendocrine prostate cancer with BRCA1 mutation: a case report

Kaitsumaru, Masashi; Shiota, Masaki; Takamatsu, Dai; Blas, Leandro; Matsumoto, Takashi; Inokuchi, Junichi; Oda, Yoshinao; Eto, Masatoshi

doi:10.1007/s13691-022-00592-5

Cited by 4 publications

(3 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Recently, several cases of t‐NEPC treated with olaparib have been reported. The clinical features of seven previously reported cases and the present case are summarized in Table 1 13–18 . Three patients exhibited a partial response to olaparib.…”

Section: Discussionmentioning

confidence: 83%

See 1 more Smart Citation

Treatment‐related neuroendocrine prostate cancer with BRCA2 germline mutation treated with olaparib

Ikeda,

Matsuoka,

Inoue

et al. 2023

IJU Case Reports

View full text Add to dashboard Cite

IntroductionThe efficacy of olaparib for treatment‐related neuroendocrine prostate cancer is unknown. Here, we report a case of treatment‐related neuroendocrine prostate cancer with a BRCA2 mutation that was treated with olaparib with 1‐year efficacy.Case presentationA 75‐year‐old man initially diagnosed with prostate adenocarcinoma developed treatment‐related neuroendocrine prostate cancer after 10‐year androgen deprivation therapy. Despite the initial temporary effects of etoposide and carboplatin, the patient experienced prostate bed tumor recurrence 1 year after chemotherapy cessation. FoundationOne® detected a BRCA2 gene mutation, and olaparib was initiated after repeating one chemotherapy course using the same chemotherapeutic agents. The patient received olaparib with sustained tumor regression for 1 year without severe side effects.ConclusionOlaparib may be the treatment of choice for treatment‐related neuroendocrine prostate cancer in patients with BRCA mutations.

show abstract

Section: Discussionmentioning

confidence: 83%

“…The clinical features of seven previously reported cases and the present case are summarized in Table 1. [13][14][15][16][17][18] Three patients exhibited a partial response to olaparib. However, in most cases, the efficacy of olaparib in treating t-NEPC was observed only for a short duration (<6 months).…”

Section: Discussionmentioning

confidence: 99%

Treatment‐related neuroendocrine prostate cancer with BRCA2 germline mutation treated with olaparib

Ikeda,

Matsuoka,

Inoue

et al. 2023

IJU Case Reports

View full text Add to dashboard Cite

show abstract

“…A previous study reported that DDX3X [923], ZFP36 [882], FKBP5 [944], CDC25B [976], TRIB3 [948], hsa-mir-1277-5p [1469], MAX (MYC associated factor X) [1470] and STAT3 [1471] are altered expressed in respiratory viral infections. MAPK6 [854], BRCA1 [1472] and STAT3 [1473] are found to be associated with pneumonia. ZFP36 [981], FKBP5 [1046], TRIB3 [1051], PHGDH (phosphoglycerate dehydrogenase) [1100], BRCA1 [1474], SREBF2 [1475], ESR1 [1476] and STAT3 [1477] plays a vital role in the development of obesity.…”

Section: Discussionmentioning

confidence: 99%

Identification of key genes and biological pathways in chronic obstructive pulmonary disease using bioinformatics and next generation sequencing data analysis

Vastrad,

Vastrad

2024

Preprint

View full text Add to dashboard Cite

Identification of accurate biomarkers is still particularly urgent for improving the poor survival of chronic obstructive pulmonary disease (COPD) patients. In this investigation, we aimed to identity the potential biomarkers in COPD via bioinformatics and next generation sequencing (NGS) data analysis. In this investigation, the differentially expressed genes (DEGs) in COPD were identified using NGS dataset (GSE239897) from Gene Expression Omnibus (GEO) database. Subsequently, gene ontology (GO) and pathway enrichment analysis was conducted to evaluate the underlying molecular mechanisms involved in progression of COPD. Protein-protein interaction (PPI), modules, miRNA-hub gene regulatory network and TF-hub gene regulatory network analysis were performed to determine the hub genes, miRNAs and TFs. The receiver operating characteristic (ROC) analysis was performed to determine the diagnostic value of hub genes. A total of 956 overlapping DEGs (478 up regulated and 478 down regulated genes) were identified in the NGS dataset. DEGs were mainly associated with GO functional terms and pathways in cellular response to stimulus. response to stimulus, immune system and neutrophil degranulation. There were 10 hub genes (MYC, LMNA, VCAM1, MAPK6, DDX3X, SHMT2, PHGDH, S100A9, FKBP5 and RPS6KA2) identified by PPI, modules, miRNA-hub gene regulatory network and TF-hub gene regulatory network analysis. In conclusion, the DEGs, relative GO terms, pathways and hub genes identified in the present investigation might aid in understanding of the molecular mechanisms underlying COPD progression and provide potential molecular targets and biomarkers for COPD.

show abstract

Docetaxel/olaparib/prednisolone

2023

Reactions Weekly

View full text Add to dashboard Cite

Interstitial pneumonia after regression by olaparib for neuroendocrine prostate cancer with BRCA1 mutation: a case report

Cited by 4 publications

References 29 publications

Treatment‐related neuroendocrine prostate cancer with BRCA2 germline mutation treated with olaparib

Treatment‐related neuroendocrine prostate cancer with BRCA2 germline mutation treated with olaparib

Identification of key genes and biological pathways in chronic obstructive pulmonary disease using bioinformatics and next generation sequencing data analysis

Docetaxel/olaparib/prednisolone

Contact Info

Product

Resources

About